Welcome to our dedicated page for iBio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on iBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into iBio's regulatory disclosures and financial reporting.
Affinity Healthcare Fund, LP and its investment adviser Affinity Asset Advisors, LLC disclosed a passive stake in iBio, Inc. The filing reports the Fund holds economic and voting interests in warrants exercisable into 4,280,000 shares of iBio common stock, representing 9.99% of the class on a reported basis. The filing explains a beneficial ownership limitation that prevents full exercise of all warrants without exceeding 9.99%, meaning the maximum number of shares that may be issued upon exercise without breaching that limit is 2,391,070. Voting and dispositive power over the reported securities are shared between the Fund and the Advisor.
Point72 entities and Steven A. Cohen reported beneficial ownership of 14,289,118 shares of iBio, Inc. common stock, representing 9.9% of the outstanding class as of August 22, 2025. The reported position includes 14,280,000 shares issuable upon exercise of warrants, but those warrants are subject to a 9.99% exercise blocker so some warrants are not currently exercisable.
The filing states Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen share voting and dispositive power over the reported shares through Point72 Associates and related arrangements. The cover pages and Item 4 disclose shared voting and dispositive power only; none of the reporting persons claim sole voting or dispositive power over the reported shares.
iBio, Inc. reported a material event filing that discloses a financing-related package of documents. The filing attaches an underwriting agreement with Leerink Partners as representative of the underwriters, forms for a pre-funded warrant and two series of warrants, a legal opinion and consent from Blank Rome LLP, and two press releases described as a launch release and a pricing release. The filing also includes the interactive cover page data file. The disclosure signals a planned securities offering structure but does not include offering size, pricing terms, or proceeds in the attached exhibit list.
iBio, Inc. filed a prospectus supplement on Form 424B5 describing a securities offering that includes pre-funded warrants, Series G and Series H warrants, and related common stock issuances. The underwriters receive a commission equal to 6.0% of aggregate gross proceeds. The filing lists outstanding and reserved equity instruments as of March 31, 2025 and August 11, 2025, including stock options (weighted-average exercise prices $5.15 and $5.92), pre-funded warrants with a $0.0001 exercise price, previously issued warrants with weighted-average exercise prices of $2.30 and $1.30, and shares reserved under the 2023 Omnibus Equity Incentive Plan. The document discusses use of proceeds, risk factors, plan of distribution, restrictions on transfers and lock-up provisions, U.S. and non-U.S. holder tax rules, and where SEC filings are incorporated by reference. The prospectus also describes iBio’s AI-driven epitope engine, capital-efficient strategy emphasizing partnerships, tech licensing, and in-house preclinical programs focused on oncology, obesity and cardiometabolic diseases.
iBio, Inc. filed a current report describing preliminary financial data and an updated business focus on AI-driven obesity and cardiometabolic therapies. On an unaudited basis, the company expects to report cash, cash equivalents and restricted cash of $8.8 million as of June 30, 2025, noting that this figure may change once year-end closing and the audit are completed.
The company outlines a preclinical pipeline centered on antibody therapeutics IBIO-610 and IBIO-600, which target pathways involved in fat-selective weight loss and muscle preservation, including in combination with GLP-1 receptor agonists. iBio also highlights its AI Drug Discovery Platform and related tools, as well as new and expanded risk factors around licensed intellectual property, reliance on AI/ML and third-party data, competitive pressures, regulatory uncertainty for AI, and the inherent difficulty and long timelines of bringing its early-stage product candidates through clinical development.
iBio, Inc. filed a prospectus supplement for an offering that includes Series G warrants and Series H warrants (the latter issuable upon exercise of Series G warrants) and related pre-funded warrants or common stock. The underwriting fees include a 6.0% commission on aggregate gross proceeds. The document discloses outstanding equity-linked instruments as of March 31, 2025 and August 11, 2025, including stock options, restricted stock units, previously issued pre-funded warrants and warrants, and shares reserved under the 2023 Omnibus Equity Incentive Plan, which create dilution potential. The prospectus describes intended use of proceeds, risk factors (including that warrants may expire worthless), tax withholding rules for non-U.S. holders, and lists incorporated SEC filings and periodic reports. The supplement also highlights the company’s AI-based epitope engine, its capital-efficient strategy emphasizing strategic partnerships, tech licensing and advancing in-house preclinical programs.
ADAR1-affiliated investors report beneficial ownership of 1,794,055 shares of iBio, Inc., representing 9.9% of the outstanding common stock. The holding comprises 54,819 shares held directly by ADAR1 Partners, LP and 1,739,236 shares issuable upon conversion of milestone warrants held by ADAR1 Partners, LP. The filing states that 716,904 additional shares underlying milestone warrants are excluded because their exchange or exercise is subject to a 9.99% beneficial ownership limitation.
The reporting entities are ADAR1 Capital Management, LLC (investment adviser), ADAR1 Capital Management GP, LLC (general partner) and Daniel Schneeberger (manager), each disclosing shared voting and dispositive power over the 1,794,055 shares. The ownership percentage is calculated on a stated base of 16,219,281 shares outstanding.
iBio, Inc. (Nasdaq: IBIO) has filed a Form 424(b)(3) prospectus dated June 23, 2025 to register the resale of up to 11,253,370 shares of common stock. The shares correspond to the same number of shares underlying New Warrants issued in a private placement completed on April 30, 2025 under an Inducement Agreement signed April 29, 2025.
- Warrant terms: exercise price $0.86, immediately exercisable, five-year term.
- Potential company proceeds: up to approximately $9.7 million in cash should all warrants be exercised.
- Use of prospectus: enables the Selling Stockholders (and their transferees) to sell shares at market, related, or negotiated prices; iBio will not receive sale proceeds but will cover registration expenses.
- Selling mechanics: shares may be sold via underwriters, brokers, or directly in public or private transactions as detailed in the “Plan of Distribution.”
- Listing information: IBIO last traded at $0.771 on June 20, 2025, below the warrant exercise price.
The filing satisfies iBio’s contractual obligation to register the shares, preserves potential capital inflow from future warrant exercises, and signals possible dilution if the warrants are exercised. Investors should consult the “Risk Factors” section on page 5 and the company’s SEC filings for further details.